These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients.
    Author: Hedner T, Pettersson A, Persson B.
    Journal: J Hypertens Suppl; 1986 Apr; 4(1):S91-3. PubMed ID: 2939221.
    Abstract:
    Pharmacokinetic and antihypertensive effects of the S2-serotonergic antagonist ketanserin were determined in 10 patients with essential hypertension (WHO stages I-II) after a single intravenous (0.15 mg/kg) and a single oral (40 mg) dose as well as during steady-state conditions on 40 mg once-daily dose regimen. The maximal plasma concentration (Cmax) of 99 +/- 14 and 97 +/- 14 ng/ml occurred approximately 1 h after single oral and chronic oral intake, respectively. The minimum steady-state concentration (Cssmin) was 13 +/- 2 ng/ml on a 40 mg once-daily regimen. Terminal half-lives (T1/2 beta) were 6.5 +/- 0.4 and 9.0 +/- 0.9 h after intravenous and single oral administration. During steady-state therapy the elimination half-life (24.7 +/- 2.6 h) was significantly increased compared to single dose administration. Bioavailability ranged between 15 and 60%, indicating a substantial first-pass effect. After intravenous ketanserin, mean supine systolic blood pressure (SBP) and diastolic blood pressure (DBP) were maximally reduced after 30 min. A single oral 40 mg dose reduced mean supine SBP/DBP by 31 +/- 8/16 +/- 5 (P less than 0.01/P less than 0.05) at maximal plasma ketanserin concentrations. The SBP and DBP were reduced over 24 h during steady-state conditions on 40 mg once-daily treatment and the mean supine blood pressure reduction 24 h after dose intake was 23 +/- 7/16 +/- 4 mmHg compared to placebo control (P less than 0.05/P less than 0.01). The data from this study indicate that ketanserin monotherapy may lower blood pressure over 24 h in a once-daily regimen.
    [Abstract] [Full Text] [Related] [New Search]